The raised guidance and strong Q3 beat, combined with FDA IDE approvals for ENHANCE Heart Part B and DENOVO Lung trials, signal accelerating commercial momentum and a clear pipeline catalyst path into 2027. Monitor enrollment progress in these trials and European expansion for further upside.
Price Chart
Executive Summary
TransMedics reported Q3 2026 revenue of $203.0M (+41% YoY) and GAAP EPS of $0.46, beating consensus estimates of $177.1M and $0.29. The company raised full-year 2026 revenue guidance to $764-$774M (including PAD Aviation), up from prior guidance of $737-$757M, driven by record case volume and strong execution in the National OCS Program.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $203.0M, up 41% YoY, beating $177.1M consensus
- GAAP diluted EPS $0.46 vs consensus $0.29 (beat)
- Adjusted diluted EPS $0.51
- Full-year 2026 revenue guidance raised to $764-$774M (incl. PAD Aviation), up from $737-$757M
- Product revenue $113.4M (+29% YoY), service revenue $89.6M (+60% YoY)
- Net income $17.1M vs $24.3M in Q3 2025; GAAP EPS $0.46 vs $0.66 YoY
- Cash $493.0M as of September 30, 2026
- Completed enrollment in ENHANCE Heart Part A; received FDA IDE approvals for ENHANCE Heart Part B and DENOVO Lung trials
- Awarded first European transplant logistics tender in Italy
Financial Impact
Revenue beat consensus by $25.9M (14.6%); EPS beat consensus by $0.17 (58.6%); full-year guidance raised by $27M at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product | $113.4M | +29.0% |
| Service | $89.6M | +60.0% |
Risk Factors
- GAAP EPS declined YoY ($0.46 vs $0.66) due to higher operating expenses and interest costs
- Operating margin contracted 230bps YoY to 13.9%
- Dependence on continued adoption of National OCS Program and regulatory approvals for new indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302931330 |
Track record
9 reports on TMDX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +22.27% at T+60 after the Jun 11, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $90.95 Now $92.21 +1.39% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $88.24 to $91.38 Now $92.21 +4.50% ▲ +3.56% +0.96% vs SPY
- Nov 5, 202611d ago Press Release Bullish 6/10 Viewing No price data
- Jun 12, 202622w ago Institutional Cluster Bullish 6/10 Entry $72.91 to $78.79 Now $92.21 +26.47% ▲ +8.06% +7.39% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bullish 5/10 Entry $73.59 to $73.22 Now $92.21 +25.30% ▼ −0.50% −0.94% vs SPY
- Apr 10, 202631w ago DEFA14A Neutral 3/10 Entry $114.00 to $115.87 Now $92.21 −19.11% ▲ +1.64% −2.86% vs SPY
- Mar 2, 202637w ago Insider Cluster Neutral 3/10 Entry $147.00 to $134.77 Now $92.21 −37.27% ▼ −8.32% −7.11% vs SPY
- Feb 27, 202637w ago 8-K Neutral 4/10 Entry $145.26 to $129.61 Now $92.21 −36.52% ▼ −10.77% −8.79% vs SPY
- Feb 24, 202637w ago 8-K Bullish 8/10 Entry $131.85 to $147.66 Now $92.21 −30.06% ▲ +11.99% +13.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers